High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: Results of an international multicenter collaborative study
Top Cited Papers
Open Access
- 22 June 2011
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (11), 3625-3632
- https://doi.org/10.1002/art.30512
Abstract
Objective Chronic infantile neurologic, cutaneous, articular (CINCA) syndrome, also known as neonatal‐onset multisystem inflammatory disease (NOMID), is a dominantly inherited systemic autoinflammatory disease. Although heterozygous germline gain‐of‐function NLRP3 mutations are a known cause of this disease, conventional genetic analyses fail to detect disease‐causing mutations in ∼40% of patients. Since somatic NLRP3 mosaicism has been detected in several mutation‐negative NOMID/CINCA syndrome patients, we undertook this study to determine the precise contribution of somatic NLRP3 mosaicism to the etiology of NOMID/CINCA syndrome. Methods An international case–control study was performed to detect somatic NLRP3 mosaicism in NOMID/CINCA syndrome patients who had shown no mutation during conventional sequencing. Subcloning and sequencing of NLRP3 was performed in these mutation‐negative NOMID/CINCA syndrome patients and their healthy relatives. Clinical features were analyzed to identify potential genotype–phenotype associations. Results Somatic NLRP3 mosaicism was identified in 18 of the 26 patients (69.2%). Estimates of the level of mosaicism ranged from 4.2% to 35.8% (mean ± SD 12.1 ± 7.9%). Mosaicism was not detected in any of the 19 healthy relatives (18 of 26 patients versus 0 of 19 relatives; P < 0.0001). In vitro functional assays indicated that the detected somatic NLRP3 mutations had disease‐causing functional effects. No differences in NLRP3 mosaicism were detected between different cell lineages. Among nondescript clinical features, a lower incidence of mental retardation was noted in patients with somatic mosaicism. Genotype‐matched comparison confirmed that patients with somatic NLRP3 mosaicism presented with milder neurologic symptoms. Conclusion Somatic NLRP3 mutations were identified in 69.2% of patients with mutation‐negative NOMID/CINCA syndrome. This indicates that somatic NLRP3 mosaicism is a major cause of NOMID/CINCA syndrome.Keywords
This publication has 17 references indexed in Scilit:
- Somatic gene mutation and human disease other than cancer: An updateMutation Research, 2010
- A somatic NLRP3 mutation as a cause of a sporadic case of chronic infantile neurologic, cutaneous, articular syndrome/neonatal‐onset multisystem inflammatory disease: Novel evidence of the role of low‐level mosaicism as the pathophysiologic mechanism underlying mendelian inherited diseasesArthritis & Rheumatism, 2010
- The NLRP3 Inflammasome: A Sensor for Metabolic Danger?Science, 2010
- Initial description of the human NLRP3 promoterGenes & Immunity, 2008
- Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patientsBlood, 2008
- Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 geneActa Paediatrica, 2006
- Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 geneActa Paediatrica, 2006
- Somatic mosaicism of CIAS1 in a patient with chronic infantile neurologic, cutaneous, articular syndromeArthritis & Rheumatism, 2005
- Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCUBlood, 2004
- Two German CINCA (NOMID) patients with different clinical severity and response to anti‐inflammatory treatmentEuropean Journal of Haematology, 2003